Second Annual
Scripps Cardiomyopathy and Cardio-Oncology Symposium:
A Case-Based Approach

SEPTEMBER 21, 2019
THE SCHAETZEL CENTER • SCRIPPS MEMORIAL HOSPITAL
LA JOLLA, CALIFORNIA

Visit www.scripps.org/cardiomyopathycme to register online!
Course Overview
The Scripps Cardiomyopathy and Cardio-Oncology Symposium is designed to provide a state-of-the-art, comprehensive, case-based curriculum that addresses important clinical topics relevant to cardiomyopathy and cardiovascular health of cancer survivors. Cardio-oncology is a growing field that has great importance as newly developed cancer treatments improve cancer survival rates but can be associated with cardiovascular toxicities. Similarly cardiac amyloidosis is a burgeoning disease with exciting new treatments. The program is intended for those involved in the care of patients with cardiomyopathies, diastolic heart failure, chemotherapy or radiation induced heart disease, pulmonary hypertension, and cardiomyopathy related arrhythmic diseases.

Nationally recognized faculty will cover challenging heart failure topics related to common cardiomyopathies, role of hemodynamic testing, latest structural heart therapies, ventricular assist devices and transplantation, cardio-oncology, cardiac imaging, electrophysiology, and genomics. The goal of the conference is for participants to return to their practice equipped with the latest evidence base and practical information to improve patient care.

Educational Objectives
After attending this live activity, participants should be able to:
- Assess the risks of oncologic treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.
- Implement strategies for early detection, correction of cardiac risk factors, and close and long-term cardiac monitoring in order to reduce the effects of cardiotoxicity for patients who are at risk of cancer treatment-related cardiac dysfunction, including heart failure, valvular dysfunction and autonomic dysfunction.
- Recognize potential cardiovascular complications of novel molecular targeted therapies, including arrhythmias, cardiomyopathy, cardiac ischemia, and hypertension.
- Critically evaluate multi-modality imaging such as cardiac magnetic resonance (MR), echocardiography, and nuclear imaging including positron emission tomography (PET) scanning in the diagnosis and follow-up of cardiomyopathy.
- Describe patient selection for advanced diagnostics for dyspnea.
- Identify common clinical and diagnostic criteria that would prompt a detailed pulmonary hypertension evaluation.
- Apply recommendations from the recently updated ACC/AHA/Heart Failure Society of America (HFSA) guidelines when diagnosing and managing patients with cardiomyopathy.
- Discuss the latest diagnosis and treatment options available for cardiac amyloidosis.
- Incorporate guidelines and algorithms for the evaluation and management of patients with syncope, sudden cardiac death, and cardiac sarcoidosis based on current recommendations from the ACC/AHA/Heart Rhythm Society (HRS).
- Evaluate available clinical evidence for recommendations for the management of cardiovascular disease during pregnancy.
- Identify patients who would benefit from implantable pulmonary artery sensor monitoring.
- Illustrate the importance of the multidisciplinary cardio-oncology team.

Target Audience
- Cardiologists
- Oncologists
- Internists
- Nurse Practitioners
- Physician Assistants
COURSE CO-DIRECTORS

Rajeev C. Mohan, MD
Advanced Heart Failure and Mechanical Circulatory Support Program
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

Ajay V. Srivastava, MD, FACC
Co-Director
Hypertrophic Cardiomyopathy (HCM) Clinic
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

FACULTY

Jorge A. Gonzalez, MD, FACC
Director, Advanced Cardiovascular Imaging
Co-Director
Hypertrophic Cardiomyopathy (HCM) Clinic
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

J. Thomas Heywood, MD, FACC
Director, Advanced Heart Failure and Mechanical Circulatory Support
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

Ashish N. Kabra, MD, MRCP
Cardiologist
Blue Coast Cardiology/Tri-City Medical Center
Oceanside, California

Na Mee C. Kim, MD
Division of Cardiology
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

Anuj K. Mahindra, MD
Division of Hematology and Oncology
Scripps Clinic and MD Anderson Cancer Center
La Jolla, California

Teferi Y. Mitiku, MD, FACC
Assistant Clinical Professor
Department of Internal Medicine
Division of Cardiology
University of California, Irvine
Orange, California

Evan D. Muse, MD, PhD, MCTI, FACC
Assistant Professor,
Scripps Translational Science Institute
Assistant Program Director for Research
Scripps Clinic
La Jolla, California

John D. Rogers, MD, FACC
Associate Chief, Cardiology
Director, Cardiac Pacing and Tachyarrhythmia Device Therapy
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

Michael R. Smith, MD, FASE
Director, Non-Invasive Research
Scripps Clinic and Prebys Cardiovascular Institute
La Jolla, California

Ronald M. Witteles, MD, FACC
Associate Professor of Medicine (Cardiovascular Medicine)
Co-Director, Stanford Amyloid Center
Stanford University Medical Center
Stanford, California

FACULTY DISCLOSURE

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

A complete listing of disclosures associated with this program can be found on the conference website: www.scripps.org/cardiomyopathycme and in the mobile conference app: www.grupio.com/CMP19.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 a.m.</td>
<td>Registration, Breakfast &amp; View Exhibits</td>
<td></td>
</tr>
<tr>
<td>7:45 a.m.</td>
<td>Welcome and Introductions</td>
<td>Rajeev C. Mohan, MD, Ajay V. Srivastava, MD</td>
</tr>
<tr>
<td>7:50 a.m.</td>
<td>Echo First! Clues for the Diagnosis of Cardiomyopathies</td>
<td>Michael R. Smith, MD</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>Patient with Shortness of Breath and a Normal Cardiac Work-up: What Next?</td>
<td>Ajay V. Srivastava, MD</td>
</tr>
<tr>
<td>8:50 a.m.</td>
<td>Devices in Heart Failure: Implantable Pulmonary Artery Pressure Sensors and Atrial Shunt Devices</td>
<td>J. Thomas Heywood, MD</td>
</tr>
<tr>
<td>9:20 a.m.</td>
<td>Gender-Specific Differences in Cardiomyopathies</td>
<td>Na Mee C. Kim, MD</td>
</tr>
<tr>
<td>9:50 a.m.</td>
<td>Break &amp; Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:10 a.m.</td>
<td>Keynote Address: Cardio-Oncology—Separating Myths from Reality</td>
<td>Ronald M. Witteles, MD</td>
</tr>
<tr>
<td>11 a.m.</td>
<td>AL Amyloid: Updates in Diagnosis and Treatment</td>
<td>Anuj K. Mahindra, MD</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>ATTR Cardiac Amyloidosis: More Common Than We Think; Update in Diagnosis and Treatment</td>
<td>Rajeev C. Mohan, MD</td>
</tr>
<tr>
<td>Noon</td>
<td>The Role of Genetic Testing in Cardiomyopathies: Diagnosis and Family Screening</td>
<td>Evan D. Muse, MD, PhD</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Lunch &amp; Exhibits</td>
<td></td>
</tr>
<tr>
<td>1 p.m.</td>
<td>Why Cardiac MRI? When Is an Echo Not Enough?</td>
<td>Jorge A. Gonzalez, MD</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>What's New in Hypertrophic Cardiomyopathy: Risk Assessment and Heart Failure Management</td>
<td>Jorge A. Gonzalez, MD, Ajay V. Srivastava, MD</td>
</tr>
<tr>
<td>2 p.m.</td>
<td>Prevention of Sudden Cardiac Death in Adults and Young Athletes: Risk Stratification and Implications for Screening</td>
<td>John D. Rogers, MD</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Break &amp; Exhibits</td>
<td></td>
</tr>
<tr>
<td>2:50 p.m.</td>
<td>Case Presentations</td>
<td></td>
</tr>
<tr>
<td>3:40 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Accreditation

Physicians
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Please note: ABIM MOC credits will be awarded to those who successfully complete the requirements outlined in the post-conference evaluation. Credits earned will be reported to the ABIM approximately 60 days post conference. These credits will not appear on your CME certificate from Scripps.

Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™. The majority of state boards accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of Registered Nursing regarding use of CME credit.

Physician Assistants
PAs may claim a maximum of 6.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Commercial Support
This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

Attendance Policies

Attendee Cancellation, Substitution, Refund
The course tuition is refundable, minus a $25 processing fee if your cancellation is received in writing no later than Monday, September 16, 2019. Attendee substitutions are allowed, but notification must be made in writing by September 16, 2019. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

Scripps Conference Modification or Cancellation Policy
Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.
Second Annual
Scripps Cardiomyopathy and Cardio-Oncology Symposium:
A Case-Based Approach

SEPTEMBER 21, 2019
THE SCHAETZEL CENTER • SCRIPPS MEMORIAL HOSPITAL
LA JOLLA, CALIFORNIA

Visit www.scripps.org/cardiomyopathycme to register online!